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Sickle cell disease (SCD) is one of the most common hereditary hemoglobinopathies worldwide,
affecting almost 400,000 newborns globally each year. It is characterized by chronic hemolytic anemia
and endothelial dysfunction, resulting in a constant state of disruption of the vascular system and
leading to recurrent episodes of ischemia-reperfusion injury (I/RI) to multiple organ systems. I/RI is a
fundamental vascular pathobiological paradigm and contributes to morbidity and mortality in a wide
range of conditions, including myocardial infarction, stroke, acute kidney injury, and transplantation.
I/RI is characterized by an initial restriction of blood supply to an organ, which can lead to ischemia,
followed by the subsequent restoration of perfusion and concomitant reoxygenation. Recent advances
in the pathophysiology of SCD have led to an understanding that many of the consequences of this
disease can be explained by mechanisms associated with I/RI. The following review focuses on the
evolving pathobiology of SCD, how various complications of SCD can be attributed to I/RI, and the role
of timely therapeutic intervention(s) based on targeting mediators or pathways that influence I/R
insult. (Am J Pathol 2019, -: 1e13; https://doi.org/10.1016/j.ajpath.2018.12.012)
SickleQ2 cell disease (SCD) includes a group of inherited dis-
orders caused bymutations in the hemoglobin subunit b.1 The
molecular defect was discovered by Pauling and Itano and
later described by Ingram almost 6 decades ago.1 The prom-
inence of sickle hemoglobin was seen in Africa, the Middle
East, and India several thousand years ago. These areas are
highly endemic to malaria-causing protist (Plasmodium fal-
ciparum), and sickle cell trait confers a survival advantage and
relative resistance against malaria attributable to balanced
polymorphism. However, patients with homozygous disease
(HbSS) have severe outcomes and may develop lethal com-
plications attributable to falciparum malaria.2 Today, SCD
has a measurable health and economic impact in the United
States and worldwide. This inherited disease is found in 1 of
every 365 African Americans and is responsible for approx-
imately 113,000 hospitalizations and $488 million in costs
annually.3 The clinical hallmark of SCD is episodes of acute
pain and other common manifestations, including cerebro-
vascular events, such as transient ischemic attacks, ischemic
strokes [including silent cerebral infarcts (SCIs)], intracere-
bral hemorrhages, acute chest syndrome (ACS), pulmonary
hypertension (PH), bacterial infections, splenic infarcts, and
progressive multiorgan dysfunction syndrome.3 This review
focuses on ischemia-reperfusion injury (I/RI) in SCDwith the
main emphasis on the immunopathology (neutrophils and
platelets) and discusses various I/RI-associated SCD clinical
outcomes and therapeutic interventions.
Pathobiology of SCD
SCD was originally considered to be a disease of abnormal
erythrocyte polymerization, but in recent years the trend has
shifted toward a more complex pathophysiologic makeup,
consisting of a polymerization defect, disrupted endothelial
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and cellular state, and resultant vasculopathies and organ
damage (Figure 1½F1 ).3e5
Defective Globin SynthesisQ3
SCD is caused by a mutation in the b-globin gene that
changes the sixth amino acid from glutamic acid to valine.1
This mutation produces a hydrophobic motif in the deoxy-
genated hemoglobin S (HbS) tetramer that results in binding
between the b1 and b2 chains of two hemoglobin mole-
cules.5 The resultant crystallization produces a polymer
nucleus that grows and fills the erythrocyte, disrupting its
architecture and flexibility and promoting cellular dehy-
dration and decreasing ATP content6 with physical and
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review) is the most common type of SCD occurring through
inheriting copies of the HbS gene homozygous for the sickle
mutation.5 Inheriting only 1 HbS gene results in a less se-
vere phenotype termed HbAS (heterozygote).5
Red Cell Deformability and Hemolysis in SCD
HbS polymerization results in altered erythrocyte biology that
significantly affects red blood cell (RBC) membrane stability,
increasing RBC-dependent cellular interactions, causing he-
molysis, and reducing the lifespan of sickle erythrocytes.5,8
These effects are more pronounced under deoxygenated
conditions, resulting in phosphatidylserine exposure to outer
RBC surface.5 Because of the abnormal sickle shape, sickle
red blood cells (SS RBCs) are not able to traverse small
capillaries and thus stick to the postcapillary endothelial
surface via RBC adhesion molecules, such as CD36 and
integrin a4b1,
9 where they provoke unpredictable episodes of
microvascular occlusion and premature RBC destruction
(hemolytic anemia), resulting in acute painful crisis.10
Hemolysis is driven by abnormal HbS polymerization and
promotes inflammation by scavenging nitric oxide and
metabolizing its precursor arginine, leading to an oxidative/
nitrosative stress state.11 The resultant heme loaded micro-
particles get attached to the endothelium and increase the
expression of adhesion molecules, thus promoting leukocyte
recruitment and subsequent inflammation.12 Heme-bound iron
stimulates expression of placental growth factor in erythroid
cells, which contributes to pulmonary vasoconstriction and
right ventricular hypertrophy, resulting in PH in SCD. This
ubiquitously expressedmolecule promotes Toll-like receptor 4
(TLR4) signaling in endothelial cells and macrophages,
activating NF-kB and triggering vaso-occlusion through
Weibel-Palade body degranulation and adhesion molecule
expression in SCD.13,14 Heme also stimulates neutrophils to
release their extracellular traps in SCD.15 Although the
mechanism is currently unknown, it has been suggested to be
linked with reactive oxygen species (ROS) generation in
neutrophils (Figure 1).16,17 Furthermore, heme can act as a
chemotactic molecule or by producing leukotriene B4 by
macrophages, thereby inducing neutrophil migration.15
Endothelial Dysfunction and Chronic
Inflammation
The microvasculature in SCD assumes a proinflammatory,
procoagulant, and prothrombotic state,18 with the endothe-
lium itself playing a significant role in both initiating and
maintaining the disruptive state in SCD.10,18 The hyperac-
tive endothelium in SCD leads to an enhanced RBC and
neutrophil adhesion. resulting in slowed flow and sickling in
postcapillary venules (retrograde logjamming), and subse-
quent vaso-occlusion and ischemia18 (Figure 1). Evidence
that SS RBCs may induce endothelial dysfunction has been
obtained in vitro as well as in vivo models.9 For example,
endothelial adherent SS RBCs and decreased nitric oxide
availability increase expression of adhesion molecules, such
as vascular cell adhesion molecule (VCAM)-1 and selectins
(eg, P-selectin). In addition, damaged RBCs release hemo-
globin, which is oxidized to methemoglobin. Methemo-
globin is unstable and as such rapidly releases free heme,
which can activate the underlying endothelium.14,15 In
addition, inflammatory mediators, such as interleukin (IL)-6,
monocyte chemoattractant protein-1, and platelet-activating
factor, are also released from an activated endothelium in
SCD and other disease states.5,18,19
The endothelium in SCD also plays a key role in driving
thromboinflammatory responses by releasing prothrombotic
microparticles and tissue factor from circulating endothelial
cells.18,20 Additional factors include decreased thrombomo-
dulin, tissue factor pathway inhibitor, and von Willebrand
factor.18 SCD microvasculature is also highly proangiogenic,
Figure 1 Proposed overview of the vascular immunopathology of sickle cell disease (SCD). The A6T mutation in the b-globin gene causes a G6V mutation in
the globin polypeptide, leading to the deoxygenated hemoglobin S (HbS) variant. When red blood cells (RBCs) are deoxygenated, HbS polymerizes and the
cells take on a sickle phenotype and express adhesion molecules, such as CD36, which mediate attachment with the endothelium. Hemolysis of the sickled cells
produces heme microparticles and arginase into the plasma and scavenge nitric oxide and stimulates the release of adhesion molecules, such as intracellular
adhesion molecule, vascular cellular adhesion molecule, P-selectin, and E-selectin. Tissue resident macrophages and dendritic cells secrete interleukin (IL)-23,
causing T cells to release IL-17A, which stimulates the secretion of granulocyte colony-stimulating factor (G-CSF) to activate neutrophil production. The
process of neutrophil maturation is under the control of mainly two transcription factors (PU.1 and CCAAT). Neutrophils adhere and roll along the endothelium
through selectin and integrin interactions in the direction of blood flow and are activated by chemokines along the endothelial layer. DAMPs (eg, ATP, high
mobility group 1) trigger Toll-like receptor (TLR)-4 and induce an inflammatory response with the secretion of cytokines and chemokines. They also send
activation signals to neutrophils and modulate their phenotype (aged neutrophils) that promote sickle cell vaso-occlusion. Activated platelets cause neu-
trophils to release chromatin and granule proteins to form neutrophil extracellular traps (NETs) and capture sickle RBCs (sRBCs). After activation from gly-
colipids derived from the tissue damage, invariant natural killer T (iNKT) cells cause further neutrophil recruitment and inflammation through production of
interferon-g and CXCR3 chemokines. sRBCs have phosphatidylserine externalization and express b2-adrenergic receptors, which activate their procoagulant
nature and adhesion properties, respectively. The subsequent responses consist of continuous accumulation of leukocytes, platelets, and RBCs with the
activation of the coagulation cascade. These interactions may be mediated by the production of various proinflammatory and prothrombotic mediators, such
as cathepsin G, neutrophil elastase, NETs, histones (citH3), and coagulant factors (FV and FX). Neutrophil elastase can co-localize with tissue factor pathway
inhibitor (TFPI) on NETs and facilitates TFPI degradation, resulting in an activated coagulation system. The presence of citH3on NETs is known to induce
platelet aggregation via involvement of TLR2 and TLR4. Cathepsin G can activate protease activated receptor (PAR)-4, resulting in further platelet activation.
As more blood cells become further incorporated and recruited into growing thrombi, fibrin scaffolds are formed. Under homeostatic conditions, neutrophils
generally produce annexin A1 (AnxA1), which counteracts proinflammatory responses and enables resolution. However, in SCD, AnxA1 levels are low. The
dotted lines separate the different phases of SCD vascular immunopathology.
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which has been attributed to the hypoxic environment and
increased levels of various proangiogenic factors, including
vascular endothelial growth factor, placental growth factor,
angiopoietin-1, angiopoietin-2, and erythropoietin in the cir-
culation.18,21 For further reading about the role of the endo-
thelium in SCD, please refer to the review by Hebbel et al.18
I/RI in SCD
I/RI is a well-known phenomenon associated with micro-
vascular dysfunction that occurs in a wide range of pathologic
conditions, including SCD.22 I/RI is fundamentally divided
into two discrete phases composed of an initial ischemic insult
attributable to vaso-occlusion followed by reperfusion, which
consists of a pronounced proinflammatory response both
locally and remotely (called reperfusion injury), resulting in
microvascular dysfunction.23,24 The extent of I/RI dysfunc-
tion depends on the vascular system involved, underlying
comorbidities, and most importantly the magnitude and the
duration of ischemia.24 Hence, prompt treatment for ischemic
events is paramount in I/RI-based complications.24
At a cellular level, prolonged ischemia and vaso-occlusion
trigger anerobic metabolism and lactic acid production,
resulting in ATP depletion and intracellular acidosis. As a
consequence, ATPases (eg, sodium-potassium ATPase) are
inactivated, contributing to an increase in intracellular and
mitochondrial calcium (calcium overload) attributable to
dysfunctional calcium ion efflux and reduced reuptake of
calcium ion by the endoplasmic reticulum.24 Concomitantly,
excessive production of ROS and calcium overload results in
the opening of the mitochondrial permeability transition pore,
further reducing ATP levels.24 Xanthine oxidase, which has a
significant impact on I/RI, is formed from xanthine dehy-
drogenase under hypoxic conditions and ATP catabolism.
Production of xanthine oxidase allows superoxide and
hydrogen peroxide production, initiating the overall I/RI.25
The univalent reduction of molecular oxygen in I/RI results
in the production of primary ROS superoxide anion radical
and can directly oxidize various biomolecules and inactivate
enzymes, initiate apoptosis, enhance proinflammatory stim-
uli, modify the expression of adhesion molecules on the
surface of leukocytes and endothelial cells, and promote nitric
oxide biodeficiency.22,24 Tissue hypoxia andROS production
during ischemia activate and recruit cells of innate and
adaptive immune system to the affected site, mainly via
involvement of signaling events through pattern recognition
molecules (especially TLRs, such as TLR4)22 and production
of IL-17, respectively.22 Moreover, the release of proin-
flammatory mediators in the ischemic area, such as ROS and
cytokines/chemokines from activated endothelium and
tissue-resident macrophages and mast cells, activates and
recruits leukocytes (eg, neutrophils, monocytes, and lym-
phocytes).26 In addition, there is abundant evidence that now
suggests a role of platelets in I/RI. On tissue injury, platelets
acquire an activated phenotype via glycoprotein Iba
interaction with endothelial P-selectin as well as von Wille-
brand factor and aggregate and release platelet-derived me-
diators.27 Recent evidence mainly from indirect data that
target T cells (eg, immunosuppressive agents) has suggested a
modulatory role of antigen-specific T cells and independent
responses in I/RI by mechanisms that are not yet well eluci-
dated.28 Finally, the role of the complement system in I/RI is
known to involve both classic and alternative pathways.26
The mechanisms and widespread cellular and tissue re-
sponses known in I/RI described above may explain SCD-
associated microvascular complications. I/RI in SCD can
lead to endothelial dysfunction29 through a deposition of
xanthine oxidase, cyclooxygenase, uncoupled endothelial
nitric oxide, NADPH oxidase, cytochrome p450, and the
mitochondrial electron transport chain, all of which result in
an increased vascular production of superoxide.10,30 These
events help in part to explain the risk of episodic pulmonary
arterial vasoconstriction attributable to exaggerated response
to unrelated potential vasoconstrictors (eg, hypoxia, platelet
activating factor, and incremental hemolytic rate).
Neutrophil Activation and Cellular Cross-Talk in
SCD
Leukocytes (most notably neutrophils) have been implicated
in the pathogenesis of SCD and in the genesis of the
proinflammatory and prothrombotic phenotype associated
with this disease.4,16 These immune cells have more com-
plex roles beyond that of just immune surveillance and
being first responders in innate immunity. Neutrophils also
play key roles in chronic inflammatory conditions, adaptive
immune responses, and cancer biology.31
Neutrophilia has long been considered a risk factor in SCD
and positively correlates with early death, SCIs, hemorrhagic
strokes, andACS.3 Reduction of neutrophil count with the use
of hydroxyurea markedly decreases the frequency of painful
crisis and ACS in moderate and severe SCD.4 Neutrophils in
SCD also have an activated phenotype with lower levels of L-
selectin (CD62L) and higher levels of CD64.32 Various
in vivo studies have found that SS RBCs bind to neutrophils
via up-regulation of aMB2 (Mac-1) and E-selectin.4
Neutrophil heterogeneity in patients with SCD is also
explained by microbiota regulation via danger-associated
molecular patterns, ATP, and pattern recognition re-
ceptors.32 Broad-spectrum antibiotics promote better blood
rheology and prolonged survival by depleting microbiota,
normalizing the number of aged neutrophils, and reducing the
production of neutrophil extracellular traps (NETs).32
Moreover, antibiotic use is known to cause a significant
reduction in neutrophil adhesion and Mac-1 activation.32 For
example, historical data with penicillin prophylaxis, which is
commonly given to functionally asplenic patients, to mitigate
vaso-occlusive crises (VOCs) in SCD.33
Neutrophils form an important link bridging inflam-
mation and thrombosis, a phenomenon referred to as
Ansari and Gavins
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thromboinflammation, by their ability to produce proin-
flammatory/prothrombotic mediators, such as neutrophil
serine proteases (eg, cathepsin G and neutrophil elastase)34
and chromatin structures called NETs35 on activation.
Neutrophil serine proteases can regulate proinflammatory/
prothrombotic responses by interacting with platelets,
coagulation factors,34 and binding with formyl peptide re-
ceptors on neutrophils and monocytes.36 In addition, NETs
are stimulated by pathogens as well as other stimuli (eg,
activated platelets37 and heme),16 especially under chronic
inflammatory phenotypes, such as SCD. Furthermore, a
variety of studies have found that NETs can capture plate-
lets and RBCs, forming a complex network, which can lead
to VOCs.35 Activated endothelial cells induce NET release
and kill endothelial cells.38 Our preclinical results indicate
that NETs act as prothrombotic scaffolds and play a major
role in cerebral thrombus formation (J.A., F.N.E.G., un-
published data)39 (Figure 1).
Formyl peptide receptors are G-proteinecoupled receptors
expressed mainly by myeloid cells with proinflammatory as
well as anti-inflammatory responses, depending on the dis-
ease state and ligand interaction.40 Annexin A1 is an endog-
enous anti-inflammatory/proresolving mediator secreted
mainly by neutrophils whose levels are known to be low in
patients with SCD.41 Annexin A1 is known to be protective in
I/RI-based vascular inflammation and may have a role in the
management of SCD.42
Platelets
Platelets have an essential role in the pathogenesis of SCD
by interacting constantly with RBCs, neutrophils, and
monocytes.4 Activated platelets piggyback on neutrophils,
inducing neutrophil polarization and triggering direct
migration of neutrophils to initiate inflammation in a
P-selectinedependent manner.43 Platelet function is
significantly altered in SCD and is associated with an
abnormal phenotype marked by surface-mobilized, activa-
tion-dependent antigens and microparticle formation.44
Increased circulating activated platelets have been
observed in patients with SCD45 along with increased
circulating levels of platelet products, such as thrombo-
spondin and increased expression of P-selectin (which
mediates the adhesion of erythrocytes and leukocytes in
venules of sickle cell (bS) transgenic mice).43,46 In addi-
tion, evidence exists in patients with SCD of ongoing
generation of thrombin,47 which may mediate the platelet
activation observed in this disease.
Cerebral I/RI
Clinical hallmarks of SCD, which include hemolytic ane-
mia, VOC, and vascular endothelial dysfunction, all
contribute to the increased risk of cerebral ischemic injury in
SCD,3 which constitutes 54% of all cerebrovascular
accidents48 and is one of the most devastating complications
of SCD. The risk of overt stroke for children with SCD
is >333 times higher than that for the general population,
and this burden continues well into adulthood, with
approximately 11% of patients with SCD having clinically
apparent strokes before the age of 20 years, increasing to
24% by the age of 45 years.48,49 These figures are likely to
be far greater because of the increased incidence of SCIs,
which, although quantifiable by magnetic resonance imag-
ing (MRI), produce no or subtle transient focal neurologic
signs.50 As a consequence of overt stroke or SCIs, patients
with SCD can have a global neurocognitive impairment as
well as sensory and motor deficits.51 Thus, the combined
frequency and overall burden of these ischemic events in the
brain of patients with SCD not only are likely to be
underestimated but also still remain poorly understood.
The pathophysiology of stroke induction is similar to
most other complications of SCD. The deformed and sticky
RBCs adhere to the surrounding endothelium in cerebral
vessels,52 resulting in endothelial cell damage and I/RI.
These events are followed by von Willebrand factor release,
platelet aggregation, and innate and adaptive immune sys-
tem activation as described previously.53,54 The whole
process causes further hypoxia and acidosis and conse-
quently further sickling. Prolonged exposure to ischemia
also causes irreversible and fatal consequences to resident
neurons, including cellular changes, such as nuclear frag-
mentation, chromatin condensation, and cell body
shrinkage.55 Bloodborne cells, such as T lymphocytes,
which are known to accumulate in the postischemic brain
within 24 hours, also play an important role in the detri-
mental effects associated with cerebral I/RI in SCD by
modulating the recruitment of adherent leukocytes and
platelets.56 Furthermore, increases in cerebral blood flow, as
measured by high transcranial Doppler velocity, and
platelet-derived growth factoremediated cerebral arterial
remodeling also contribute to the overall increased risk of
cerebrovascular diseases in SCD.57
Remote Organ Injury in SCD
SCD mounts a widespread systemic inflammatory
response attributable to chronic leukocyte and endothelial
cell activation, multiple elevated inflammatory mediators
(eg, IL-6, tumor necrosis factor-a, IL-1b),10 and acute-
phase reactants (eg, C-reactive peptide, secretory phos-
pholipase A2, and granulocyte colony-stimulating factor).
This persistent, unresolved inflammation may culminate in
remote organ injury or multiorgan dysfunction syndrome58
by promoting neutrophil activation, inducing generalized
leukocyte and endothelial adhesion molecule expression,
and enhancing the opportunities for leukocyte-endothelial
cell interactions.10,59 The same widespread inflammatory
response has also been seen in sickle transgenic mice with
leukocytosis, increased oxidant generation,60 and
Ischemia-Reperfusion in SCD
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heightened interactions between leukocytes and endothe-
lial cells.30
I/RI is a central pathophysiologic process that drives
remote organ injury in SCD, with the lungs being the most
vulnerable organs.24 Numerous studies have established that
remote organ injury can also occur in other organs (eg, gut,
liver, skeletal muscle, and heart).24 Xanthine oxidase, which
accumulates throughout the initial ischemic period, results
in the generation of massive amounts of ROS, endothelial
dysfunction, and xanthine oxidaseederived oxidant-induced
release of chemotactic factors, which promote leukocyte
recruitment. The postischemic blood also causes priming
















Figure 2 Schematic depiction of potential therapeutic targets in sickle cell disease (SCD). The depicted targets have been tested as potential therapeutics
for ischemia reperfusion injury (I/RI) and its associated symptoms in SCD. A: Red blood cell (RBC) ion channel blockers (Gardos channel blockers, eg,
senicapoc) can preserve sickle RBC (sRBC) hydration and improve survival. B: Hydroxyurea acts by inducing fetal hemoglobin (HbF), donating nitric oxide (NO),
and decreasing circulating leukocytes and reticulocytes. C: Anticoagulants, such as direct thrombin inhibitors (eg, dabigatran), will reduce thromboin-
flammation. D: Antioxidants, such as arginine and L-glutamine, reduce the oxidant stress by improving NAD redox potential. E: Antiadhesion agents prevent
cellular rolling and adhesion to the endothelium by decreasing the expression of intercellular adhesion molecule (ICAM), vascular cell adhesion molecule
(VCAM), E-selectin, and P-selectin (eg, rivipansel and crizanlizumab). F: b-blockers and mitogen-activated protein/extracellular signal-regulated kinase (MEK)
inhibitors reduce sRBC adhesion to the vascular endothelium and can be used for management of acute vaso-occlusive episodes. G: HbF-inducing factors, such
as hydroxyurea, and other agents (eg, decitabine, pomalidomide, butyrates) can increase HbF, lessen the HbS load, and decrease the rate of hemolysis. H:
Nitric oxideerelated agents may act by vasodilation and inhibition of vascular remodeling. I: Anti-inflammatory agents include antiadhesion agents,
adenosine A2A receptors, and b2-adrenergic pathways, which will help manage SCD by reducing overall inflammation and ischemia-reperfusionerelated injury.
J: Antiplatelet agents may reduce overproinflammatory tone, decrease platelet activation and aggregation, and reduce expression of adhesion molecules and
selectins. Green arrows indicate activation/stimulation; brown lines, inhibition.
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Table 1 Emerging Ischemia and Reperfusion Therapeutics in SCD
























L-Arginine (IV) Nitric oxide substrate Reduction in VOCs,
reduction in total opioid
use, significant decrease
in length of stay in the
hospital
Nothing significant 67e69 (NCT01142219III,
NCT00513617II, and
NCT01142219III)
L-glutaminey (oral) NAD precursor Improves altered
erythrocyte NAD redox
potential, significant








Anti-inflammatory and antineutrophil agents
Rivipansel (IV) Pan-selectin inhibition Faster VOC resolution,
reduction in hospital
stay and use of opioids
for pain management
Nothing significant 71,72 (GMI-1070 and
NCT00911495I/II)










In vivo murine model
suggests decrease in
erythrocyte adhesion,
normal blood flow, and
decrease in VOCs
Bleeding risk, HIT 74e76 (NCT0251838II)
Regadenoson A2AR agonist, iNKT
inhibition



































Reduction the duration and
severity of pain crisis
Phase 3 showed no effect 82 (NCT00004408III and
NCT01737814III)
IVIG Antibody binding via the
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Therapeutic Strategies for Treating I/RI in SCD
Despite the discovered molecular nature of SCD, huge
disparities exist in developing therapies compared with
other diseases, mainly because of the limited investment
from the pharmaceutical industry and marginal clinical tri-
als. Hydroxyurea, exchange blood transfusions, and the
recently approved L-glutamine are currently the only avail-
able disease-modifying therapies.3 Most of the focus of the
treatment to date has been on the symptomatic and pre-
ventive aspects of the disease, including antibiotic prophy-
laxis, routine immunizations, and management of acute
painful crisis with appropriate analgesia and hydration.3
Successful stem cell transplantation can cure sickle cell
anemia, but it is only performed in a few patients (with
variable outcomes) because of its high cost, lack of suitable
donors, widespread complications, and lack of availability
in every center.61 Other recent strategies lie in the field of
gene editing. Using CRISPR-Cas9 gene editing, scientists
have been able to repair the defective genes in cells taken
from patients with SCD by up to 25%, although less success
was observed when the edited cells were tested in vivo.62
However, this idea of correcting the gene is far from
being a readily available and acceptable clinical strategy for
the treatment (and cure) of SCD.
The main focus of SCD management has been on the
associated pain, which has given good short-term benefits
without a substantial long-term therapeutic impact. Under-
standing the complex pathophysiologic mechanisms of SCD
has led to multiple potential targets in the I/RI cascade, which
may have long-term beneficial outcomes (Figure 2½F2 and
Table 1 ½T163e89). Some of these targets and strategies are dis-
cussed here.
AntiSickling Agents
Antisickling is the most common disease-modifying strategy
in SCD. These agents increase fetal hemoglobin (HbF) levels,
lessen the HbS load, and decrease the rate of hemolysis.3 The
most common antiswitching agent used is hydroxyurea; other
agents that result in HbF induction have not proven to be as
efficacious. Hydroxyurea was approved by the US Food and
Drug Administration (FDA) for use in SCD in February 1998
and is believed to be acting via multiple pathways to induce
HbF,90 although the actual mechanism of action is still under
debate. However, it is known whether hydroxyurea acts as a
nitric oxide donor,91 stabilizing erythrocyte structure and
decreasing circulating leukocytes and reticulocytes, all of
which mitigate I/RI in SCD.92
Multiple trials have evaluated the role of hydroxyurea in
SCD in both adults and children, demonstrating reductions
in severity and frequency of VOC.93,94 Furthermore, hy-
droxyurea significantly decreases adhesion molecules, such
as VCAM-1, and reduces the adhesion of RBCs to the
endothelium.95 There are many trials in progress with
different end points [eg, HbF response, acute complications,
maximum tolerated dose, and percentage of dense RBCs
(NCT01960413, NCT02225132, NCT02042222)]. Of in-
terest, other HbF-inducing agents (eg, decitabine, pomali-
domide, butyrates ACY-957, Pracinostat, KLF1-ASOs,
valproic acid, and trichostatin) are in preclinical or clinical
testing or in development.3
Table 1 (continued )
Intervention Target Action and advantages
Disadvantages and adverse
reactions References
Antiplatelet and anticoagulant therapy










Bleeding abnormalities 87 (NCT02072668II)
Prasugrel P2Y12 inhibition Reduce platelet activation
and vaso-occlusive pain,










yUS Food and Drug Administration approved.
zUS Food and Drug Administration approved for a rare pediatric disease designation.
A2AR, adenosine A2A receptor; BCAM/Lu, basal cell adhesion molecule and its isoform Lutheran; CNS, central nervous system; eNOS, endothelial nitric oxide
synthase; HIT, heparin induced thrombocytopenia; ICAM-4 (LW), I]intercellular adhesion molecule-4 (Landsteiner-Wiener blood); iNKT, invariant natural killer
T; IV, intravenous; IVIG, intravenous immunoglobulin; NR, not recorded; PAD, peripheral artery disease; PDE5, phosphodiesterase type 5 inhibitor; SCD, sickle
cell disease; VOC, vaso-occlusive crisis.
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Anti-Inflammatory Agents and Antineutrophil Agents
Many aspects of SCD, including multifocal microvascular
occlusions and chronic inflammation, are consistent with I/RI.
Targeting mechanisms of the inflammatory cascade, such
as adhesive interactions between cellular components
(eg, leukocytes, platelets, RBCs, and the endothelium), are of
great interest as therapeutic targets.10 Table 1 provides a
comprehensive list of anti-inflammatory and antioxidant
agents that have been tried in various studies. Some drugs and
receptors or pathways of particular interest are as follows.
Selectin Inhibitors
Selectins mediate cellular rolling and adhesion to the endo-
thelium. In particular, endothelial cells, as well as platelet-
derived P-selectin, have a key role in the pathogenesis of
VOCs, andP-selectinmediates adhesionofSSRBCs tovessels
and assists in the formation of neutrophil-platelet aggregates.73
In vivo studies have found that inhibition of adhesion mole-
cules reduces VOCs significantly,30,73,96 with the most
commonly studied antiadhesive agent, the pan-selectin inhib-
itor GMI-1070 (rivipansel), reducing VOCs and disease
severity in vivo.96 A recently completed phase 1/2 study found
high tolerability of GMI-1070 and suggested increased blood
flow in a subset of patients (NCT00911495).71 Telen et al72
completed a phase 2 study, which revealed clinically relevant
reductions in time of resolution of VOCs, length of stay in the
hospital, and opioid dose needed after GMI 1070 administra-
tion (NCT01119833).
Several studies have found positive effects in specifically
blocking P-selectin. In a recent double-blind, randomized,
placebo-controlled phase 2 trial, patients receiving a high dose
of P-selectin inhibitor crizanlizumab (SelG1) had a signifi-
cantly lower rate of sickle cellerelated pain crises than pla-
cebo.73 Sevuparin (low-molecular-weight heparin) has low
anticoagulant activity but is a potent P-selectin blocker,
inhibiting HbSS RBC adhesion to the endothelium and
reducing tumor necrosis factoreinducedVOCs.76 Sevuparin is
currently undergoing a phase II trial (NCT0251838) for the
management of acute VOCs.
Adenosine A2A Receptors and b2-Adrenergic Pathway
The b2-adrenergic system also plays a significant role in
adhesion pathways via activation of basal cell adhesion
molecule and its isoform Lutheran and intercellular adhesion
molecule-4 (Landsteiner-Wiener blood).81 Epinephrine ele-
vates cAMP and increases adhesion in a B-adrenergic and
protein kinase Aedependent manner (NCT02012777).81
Invariant natural killer T (iNKT) cells become activated and
increase in number during painful VOCs in SCD. Concomi-
tantly, there is an increase in NF-kB phosphorylation, an in-
crease in adenosine A2A receptor expression, and an increase
in interferon-g levels, all instigating inflammation during
VOCs. Adenosine A2A receptor agonists can decrease the
iNKT cell activation and may limit painful crisis in SCD. In a
recent phase 1 study, regadenoson, an adenosine A2A receptor
agonist, reduced the activation of iNKT cells without causing
any toxic effects.77 However, the phase 2 trial did not find any
improvement in the clinical outcomes and nonsignificant
reduction of iNKT cell activation between regadenoson treat-
ment and placebo groups in SCD.97 Sulfasalazine is a potent
and specific inhibitor of NF-kB activation78 and modulates
endothelial function and significantly ameliorates secondary
inflammatory damage (by reducing the expression of inter-
cellular adhesion molecule, E-selectin, and VCAM, thus
decreasing leukocyte recruitment) caused by SCD in multiple
animal and human studies.79,98,99
Targeting Neutrophils by IVIGs
The working mechanism of immunomodulation by intrave-
nous immunoglobulins (IVIGs) is still not completely under-
stood, but research in the last decade has primarily focused on
classic antibody binding via the Fc-domain of the IgG mole-
cules to the common IgG receptors. Multiple studies have
found a role of IVIG in modulating neutrophil activation,
decreasing RBC-neutrophil interactions, inhibiting adhesion,
and increasing their flow and survival.83 These effects are
mainly mediated via neutrophil specific FcgRIII receptors84
and Mac-1.85 An ongoing phase 1/2 trial (NCT01757418) is
currently recruiting patients to assess the effects of IVIG on
sickle cell pain crisis. In contrast to GMI-1070, low-dose IVIG
at 200 to 400mg/kg may have a better overall efficacy because
of less of an increase in white blood cell and neutrophil counts,
resulting in an increased effect on RBC capture.85
Antiplatelet and Anticoagulants
Although drugs that target the generation (eg, warfarin) or
activity (eg, heparin) of thrombin have been tested for pre-
vention of sickle cell crises, high oral doses proved not to be
beneficial because of major bleeding complications.100 How-
ever, lower doses,whichmay have greater benefit, have not yet
been evaluated in randomized trials in patients with SCD.
Nonetheless, thrombin remains a viable therapeutic target for
prevention of the enhanced thrombosis in SCD.86 In a pre-
clinical study, a 10-day treatment of sickle mice with dabiga-
tran (a direct thrombin inhibitor) resulted in reduced neutrophil
infiltrates in the pulmonary tissue.86 Prasugrel, an oral P2Y12
receptor inhibitor that prevents ADP-dependent platelet acti-
vation, has been also tested in various preclinical and clinical
trials for determining effects on vaso-occlusive events; so far,
the results have failed to prove any substantial reduction.88,89
Oxidative and Nitrosative Targets
Oxidative and nitrosative stress and nitric oxide depletion play
a pivotal role in the pathophysiologic mechanisms of SCD.
Nitric oxide inhibits leukocyte adhesion and platelet adhesion
and activation, thus blunting hemolysis and thromboin-
flammation associated with SCD.10,101 Several agents that
target different aspects of oxidant and nitric oxide biology have
Ischemia-Reperfusion in SCD
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been used to modify SCD and reduce VOC events (Table 1).
Some of the particular interest are as follows.
Nitrite Therapy
Initial studies in animals, as well as humans, had some
promise with inhaled nitric oxide therapy. de Franceschi
et al63 subjected transgenic mice with SCD to hypoxia and
reoxygenation, coupled with inhalation of nitric, and found
that this prevented histopathologic lung damage, attenuated
inflammatory responses, modulated genes involved in I/RI,
modulated vascular rheology, and attenuated RBC dehydra-
tion. However, in adults with SCD and mild to moderate
ACS, nitric oxide therapy failed to show any reduction in
treatment, suggesting that nitric oxide therapy is complex and
requires further understanding.64 The failure of inhaled nitric
oxide may be because it mainly targets the lungs and was
used under acute care settings, which may have been insuf-
ficient for I/RI affected tissues101 with less systemic action.
Phosphodiesterase and Endothelin Receptor Inhibition
SCD is associated with a significant oxidant stress, which is
attributable to lower redox potential attributed mainly to
arginase release from intravascular hemolysis and endo-
thelial production under a proinflammatory state.67 The
resulting deficit in arginine is known to contribute to VOC
and early mortality.67 Preliminary clinical studies with
arginine therapy, including a phase 2 trial, found efficacy in
managing acute VOCs67 and other complications, such as
leg ulcers68 and PH.69
L-glutamine is a precursor of NAD and prevents oxidant
damage to RBCs by improving the NAD redox potential.70
A recent phase 3 trial (NCT01179217) found that it provides
clinical benefit over placebo by reducing the frequency of
painful crisis and hospitalization.102 L-glutamine was
recently approved by the FDA to reduce acute complica-
tions of SCD in adult and pediatric patients (5 years
old).103 In addition, a multicenter randomized clinical trial
of sildenafil for PH in patients with SCD (termed the walk-
PHaSST) was stopped because of serious adverse effects in
the treatment group.66 Results were also inconclusive when
endothelin receptor blockade was used (Asset-1 and -2, with
bosentan) as a potential therapy for PH.104
Conclusions
The role of I/RI in the pathophysiology of SCD is complex
and needs further understanding. Reperfusion injury attrib-
utable to ROS production and cellular activation plays a
major role in SCD and should set the stage for more robust
and durable preclinical and clinical research, ultimately
paving the way for new disease-modifying agents. In
addition, SCD is a thromboinflammatory state that con-
tributes to chronic inflammation and I/RI. Targeting various
thrombosis and coagulation mechanisms and pathways may
also be another viable therapeutic strategy for drug dis-
covery programs. The recent FDA approval of L-glutamine,
promising results with crizanlizumab, and the continued
success of hydroxyurea in both the pediatric and adult
populations have given more impetus to the study of the
various checkpoints in the I/RI-based pathophysiology in
SCD. In summary, because SCD is a systemic and wide-
spread disease that involves a panoply of cellular mediators
and pathways, a more individualized multitargeted thera-
peutic approach might be the future for SCD medicine.
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